IL248578A0 - Quinzoline derivatives, pharmaceutical compounds containing them and their uses - Google Patents

Quinzoline derivatives, pharmaceutical compounds containing them and their uses

Info

Publication number
IL248578A0
IL248578A0 IL248578A IL24857816A IL248578A0 IL 248578 A0 IL248578 A0 IL 248578A0 IL 248578 A IL248578 A IL 248578A IL 24857816 A IL24857816 A IL 24857816A IL 248578 A0 IL248578 A0 IL 248578A0
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical compositions
based compounds
scaffold based
quinazoline scaffold
Prior art date
Application number
IL248578A
Other languages
English (en)
Hebrew (he)
Original Assignee
Technion Research And Development Foundation Limited
Moshe Gavish
Marek Ilan
Avital Avi
Shterenberg Alex
Vainshtein Alex
Veenman Jehuda Arieh (Leo)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Limited, Moshe Gavish, Marek Ilan, Avital Avi, Shterenberg Alex, Vainshtein Alex, Veenman Jehuda Arieh (Leo) filed Critical Technion Research And Development Foundation Limited
Publication of IL248578A0 publication Critical patent/IL248578A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL248578A 2014-04-23 2016-10-25 Quinzoline derivatives, pharmaceutical compounds containing them and their uses IL248578A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461982880P 2014-04-23 2014-04-23
PCT/IL2015/050426 WO2015162615A1 (en) 2014-04-23 2015-04-22 Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
IL248578A0 true IL248578A0 (en) 2016-12-29

Family

ID=53276956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248578A IL248578A0 (en) 2014-04-23 2016-10-25 Quinzoline derivatives, pharmaceutical compounds containing them and their uses

Country Status (6)

Country Link
US (1) US10035780B2 (enExample)
EP (1) EP3134389B1 (enExample)
JP (1) JP6498695B2 (enExample)
CN (1) CN106458933B (enExample)
IL (1) IL248578A0 (enExample)
WO (1) WO2015162615A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458933B (zh) 2014-04-23 2021-03-05 泰克年研究发展基金会公司 基于喹唑啉支架的化合物、其药物组合物及使用方法
EP4611769A1 (en) * 2022-10-31 2025-09-10 Yeda Research and Development Co. Ltd Conditioning protocols for use with anti-viral central memory cd8+veto cells in haploidentical stem cell transplantation
WO2024095268A1 (en) * 2022-11-02 2024-05-10 Technion Research & Development Foundation Limited Translocator protein ligands and inflammatory diseases
CN116410180B (zh) * 2023-03-01 2024-09-10 青岛大学 4-氧代喹啉-3-甲酰胺衍生物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
US5716956A (en) 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
DE19617863A1 (de) 1996-04-23 1997-10-30 Schering Ag Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
EP1066039A4 (en) 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
JP2004256473A (ja) 2003-02-27 2004-09-16 Ono Pharmaceut Co Ltd エラスターゼ阻害活性を有する１，３，４−オキサジアゾール誘導体
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
EP2589597B1 (en) * 2006-08-22 2019-03-06 Technion Research & Development Foundation Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR)
CN106458933B (zh) 2014-04-23 2021-03-05 泰克年研究发展基金会公司 基于喹唑啉支架的化合物、其药物组合物及使用方法

Also Published As

Publication number Publication date
EP3134389B1 (en) 2021-04-14
JP2017513845A (ja) 2017-06-01
US20170217907A1 (en) 2017-08-03
CN106458933B (zh) 2021-03-05
JP6498695B2 (ja) 2019-04-10
CN106458933A (zh) 2017-02-22
US10035780B2 (en) 2018-07-31
WO2015162615A1 (en) 2015-10-29
EP3134389A1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
IL277069B (en) Modified aminopurine compounds, their compositions and methods of treatment with them
IL252477A0 (en) 2-aminopyrimidine compound, pharmaceutical structure and its use
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
ZA202003663B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3094606A4 (en) Cement compositions, structures, and methods of use
IL259894A (en) Improved compositions and improved methods for viral delivery of neoepitopes and their use
LT3223796T (lt) Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
PL2998311T3 (pl) Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie
PL3157506T3 (pl) Kompozycja farmaceutyczna do podawania doustnego o maskowanym smaku
SMT202000281T1 (it) Composizioni farmaceutiche e loro uso
EP3297636A4 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
IL246629A0 (en) Pharmaceutical preparations containing a derivative of benzonitrile and gefitinib
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
ZA201708339B (en) Primin derivatives, method of preparation thereof and use thereof
GB201415969D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
HK1233497A1 (en) Compositions of selenoorganic compounds and methods of use thereof